Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 4
1994 8
1995 4
1996 7
1997 11
1998 2
1999 3
2000 2
2001 2
2002 5
2003 3
2004 1
2005 2
2007 1
2009 1
2010 2
2015 2
2016 1
2017 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase.
Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Matzke M, Pleiss U, Keldenich J, Müller-Peddinghaus R. Hatzelmann A, et al. Agents Actions. 1994 Nov;43(1-2):64-8. doi: 10.1007/BF02005767. Agents Actions. 1994. PMID: 7741044 Review.
The binding of BAY X 1005 to FLAP correlates with LTB4 synthesis inhibition. BAY X 1005 has been shown to bind to the 18 kD protein FLAP. BAY X 1005 inhibits 5-LOX translocation from the cytosol to membranes and rever …
The binding of BAY X 1005 to FLAP correlates with LTB4 synthesis inhibition. BAY X 1005 has been s …
No pharmacokinetic or pharmacodynamic interaction between theophylline and the leukotriene biosynthesis inhibitor BAY x 1005.
Groen H, Moesker HL, Leeuwenkamp OR, Sollie FA, Jonkman JH. Groen H, et al. J Clin Pharmacol. 1996 Jul;36(7):639-46. doi: 10.1002/j.1552-4604.1996.tb04229.x. J Clin Pharmacol. 1996. PMID: 8844447 Clinical Trial.
Steady-state concentrations of theophylline were not affected by concomitant BAY x 1005 intake, and addition of theophylline had no clinically relevant effect on steady-state plasma concentrations of BAY x 1005. The combination of theophy …
Steady-state concentrations of theophylline were not affected by concomitant BAY x 1005 intake, and addition of theophy …
Antileukotrienes in upper airway inflammatory diseases.
Cingi C, Muluk NB, Ipci K, Şahin E. Cingi C, et al. Curr Allergy Asthma Rep. 2015 Nov;15(11):64. doi: 10.1007/s11882-015-0564-7. Curr Allergy Asthma Rep. 2015. PMID: 26385352 Review.
Antileukotriene drugs are classified into two groups: CysLT receptor antagonists (zafirlukast, pranlukast, and montelukast) and LT synthesis inhibitors (5-lipoxygenase inhibitors such as zileuton, ZD2138, Bay X 1005, and MK-0591). CysLTs have important proinf …
Antileukotriene drugs are classified into two groups: CysLT receptor antagonists (zafirlukast, pranlukast, and montelukast) and LT synthesis …
Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds.
Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R. Hatzelmann A, et al. Biochem Pharmacol. 1993 Jan 7;45(1):101-11. doi: 10.1016/0006-2952(93)90382-7. Biochem Pharmacol. 1993. PMID: 8381000
In an attempt to identify possible target proteins of BAY X 1005, [14C]BAY X 1005 was used in binding studies under equilibrium conditions. ...The analysis of BAY X 1005 binding in rat PMNL also revealed two binding s …
In an attempt to identify possible target proteins of BAY X 1005, [14C]BAY X 1005 was used in bind …
Favorable combination effects of the leukotriene synthesis inhibitor BAY X 1005 and dexamethasone on edema formation in the arachidonic acid-induced mouse ear inflammation test.
Burchardt ER, Müller-Peddinghaus R. Burchardt ER, et al. Prostaglandins Leukot Essent Fatty Acids. 1999 Jan;60(1):5-11. doi: 10.1054/plef.1998.0002. Prostaglandins Leukot Essent Fatty Acids. 1999. PMID: 10319912
In combination with BAY X 1005, the corresponding inhibition curve for dexamethasone was shifted upward starting from 56+/-13% at 0.008 mg/kg. ...In the methysergide/pyrilamine (12.5 mg/kg s.c. each)-conditioned AA-MEIT model 85+/-3% edema reduction were obse …
In combination with BAY X 1005, the corresponding inhibition curve for dexamethasone was shifted upward starting from 5 …
ABT-761 (Abbott).
Reid JJ. Reid JJ. Curr Opin Investig Drugs. 2001 Jan;2(1):68-71. Curr Opin Investig Drugs. 2001. PMID: 11527015
Abbott's ABT-761 is a 5-lipoxygenase inhibitor with 8-fold increased potency over Bay-X-1005 and 150-fold over zileuton [171665]. It has a longer duration of action than its closest competitor, ZD-2138 (AstraZeneca), and has entered phase III trials for asthm …
Abbott's ABT-761 is a 5-lipoxygenase inhibitor with 8-fold increased potency over Bay-X-1005 and 150-fold over zileuton …
Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse.
Cunningham FM, Andrews M, Landoni MF, Lees P. Cunningham FM, et al. J Vet Pharmacol Ther. 1997 Aug;20(4):296-307. doi: 10.1046/j.1365-2885.1997.00064.x. J Vet Pharmacol Ther. 1997. PMID: 9280370
Time dependent production of immunoreactive LTB4 by equine neutrophils and immunoreactive LTC4 by equine eosinophils in vitro was also demonstrated. The 5-lipoxygenase activating protein (FLAP) inhibitors, BAY X 1005 and BAY Y 1015, produced concentration dep …
Time dependent production of immunoreactive LTB4 by equine neutrophils and immunoreactive LTC4 by equine eosinophils in vitro was also demon …
Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
Gür ZT, Çalışkan B, Banoglu E. Gür ZT, et al. Eur J Med Chem. 2018 Jun 10;153:34-48. doi: 10.1016/j.ejmech.2017.07.019. Epub 2017 Jul 13. Eur J Med Chem. 2018. PMID: 28784429 Review.
The early development of FLAP inhibitors (i.e. MK-886, MK-591, BAY-X-1005) mostly concentrated on asthma cure, and resulted in promising readouts in preclinical and clinical studies with asthma patients. ...
The early development of FLAP inhibitors (i.e. MK-886, MK-591, BAY-X-1005) mostly concentrated on asthma cure, and resu …
FLAP inhibitors for the treatment of inflammatory diseases.
Sampson AP. Sampson AP. Curr Opin Investig Drugs. 2009 Nov;10(11):1163-72. Curr Opin Investig Drugs. 2009. PMID: 19876784 Review.
By blocking the formation of both leukotriene B4 and the cysteinyl leukotrienes (ie, LTC4 , LTD4 and LTE4), FLAP inhibitors act as broad-spectrum leukotriene-modifier drugs that may have a wide range of therapeutic applications. FLAP inhibitors such as MK-886, MK-0591 and velifla …
By blocking the formation of both leukotriene B4 and the cysteinyl leukotrienes (ie, LTC4 , LTD4 and LTE4), FLAP inhibitors act as broad-spe …
61 results